COAST-X trial: Ixekizumab was superior to placebo for improving signs and symptoms in patients with non-radiographic axial spondyloarthritis at weeks 16 and 52. ASAS40 at week 52 IXE q4W 30% vs. IXE Q2W 31% vs PBO 13%, p=0·0037 https://t.co/GrQnakvor1